Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Actinomycin D
Actinomycin D Catalog No.GC16866

RNA polymerase inhibitor

Size Price Stock Qty
10mM (in 1mL DMSO)
$178.00
In stock
5mg
$34.00
In stock
10mg
$62.00
In stock
50mg
$272.00
In stock
500mg
$1,895.00
In stock
1g
$3,028.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

Rat adipocytes

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.

Reaction Conditions

0, 0.1, 1 or 10 μM; 24 hrs

Applications

Actinomycin D reduced the loss of leptin mRNA accumulation over the 24-hr incubation, exhibiting maximal inhibition at the concentration of 0.1 μM.

Animal experiment [2]:

Animal models

Wistar rats

Dosage form

6 μg/μL; intrahippocampally or intracerebroventricularly

Applications

Both intrahippocampal and intracerebroventricular injection of Actinomycin D prevented a late stage of LTP in the dentate gyrus in vivo.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Fain JN, Bahouth SW. Stimulation of leptin release by actinomycin D in rat adipocytes. Biochem Pharmacol. 1998;55(8):1309-14.

[2]. Frey U, Frey S, Schollmeier F, Krug M. Influence of actinomycin D, a RNA synthesis inhibitor, on long-term potentiation in rat hippocampal neurons in vivo and in vitro. J Physiol. 1996 Feb 1;490 ( Pt 3):703-11.

Chemical Properties

Cas No. 50-76-0 SDF
Synonyms DACTINOMYCIN
Chemical Name 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
Canonical SMILES CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C
Formula C62H86N12O16 M.Wt 1255.43
Solubility ≥ 62.75 mg/mL in DMSO Storage Desiccate at 4°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

IC50: Actinomycin D showed a concentration-dependent decrease of DNA repair activity with the IC50 of 0.42 μM [1].
Actinomycin D (dactinomycin), a member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces. Have been used for many years as an older chemotherapy, actinomycin D binds to double- and single-stranded DNA to inhibit DNA and RNA synthesis by binding DNA at the transcription initiation complex and preventing elongation of RNA chain by RNA polymerase.
In vitro: A previous study was designed to determine the effects of actinomycin D on leptin release by isolated rat adipocytes during primary culture for 24 hr. Results showed that both actinomycin D and dexamethasone reduced the loss of leptin mRNA seen over the 24-hr incubation. Maximal effects on leptin release and leptin mRNA accumulation required only 0.1 μM of actinomycin D, a concentration that had no significant effect on the 18S RNA content of adipocytes at the end of a 24-hr incubation. In contrast to the reduced loss of leptin mRNA seen at 24 hr, the loss of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid (GAPDH mRNA) was enhanced in the presence of 0.1 μM of actinomycin D. These results demonstrated a unique regulation of leptin release and leptin mRNA levels by actinomycin D [2].
In vivo: A rat in vivo study showed that the effect of actinomycin D on the time course of the population spike potentiation was more pronounced than the effect on the time course of the EPSP component, suggesting different mechanisms for the two forms of potentiation. Moreover, both intrahippocampal and intracerebroventricular injection of actinomycin D prevented a late stage of LTP in the dentate gyrus in vivo measured as the population spike amplitude [3].
Clinical trial: Actinomycin is intravenously administered and most commonly used in the treatment of a variety of cancers, including gestational trophoblastic neoplasia, wilms' tumor, rhabdomyosarcoma, ewing's sarcoma and malignant hydatidiform mole. Combined with other drugs in chemotherapy regimens, such as the VAC regimen, it will be used for treating rhabdomyosarcoma and Ewing's Sarcoma. In addition, it is also used as a radiosensitizer in adjunct to radiotherapies, as it increases the tumor cells radiosensitivity.
Reference:
[1] Barret JM, Salles B, Provot C, Hill BT. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis. 1997 ;18(12):2441-5.
[2] Fain JN, Bahouth SW. Stimulation of leptin release by actinomycin D in rat adipocytes. Biochem Pharmacol. 1998;55(8):1309-14.
[3] Frey U, Frey S, Schollmeier F, Krug M. Influence of actinomycin D, a RNA synthesis inhibitor, on long-term potentiation in rat hippocampal neurons in vivo and in vitro. J Physiol. 1996;490(Pt 3):703-11.